Molecular Devices Launches Two New Platforms for Expanding Microplate Analysis

Two new microplate analysis platforms from Molecular Devices will be showcased at MipTec 2010, Switzerland. The SpectraMax® Paradigm® Platform and FilterMax™ F3 and F5 Series Readers are commercially available with shipping to begin in early October.

The SpectraMax® Paradigm® Platform is the only user-upgradeable multi-mode reader on the market today and is ideal for drug discovery research, including high-throughput screening. The FilterMax™ F3 and F5 Series Readers deliver unmatched assay performance compared to similarly priced readers and are ideal for a wide range of life science research applications.

“With these two new platforms, we now have an ideal microplate reader for any combination of application, detection, and budget needs,” said Mark Verheyden, President of Molecular Devices. “We’ve carefully expanded our portfolio to ensure that we will be able to meet our customers’ needs across ever-evolving research environments. By adding the SpectraMax Paradigm and FilterMax™ F Series Platforms to our existing lines of readers, we now offer the most comprehensive line of microplate readers on the market today.”

SpectraMax Paradigm Multi-Mode Microplate Reader
The new patent-pending SpectraMax Paradigm Platform is the only multi-mode detection platform on the market today that allows users to upgrade the functionality of their instrument directly—no service call, no factory shipment. Upgrading is as easy as selecting from over 20 mix-and-match detection cartridges and inserting them into one or more of 12 instrument slots. A single cartridge can be changed in less than 2 minutes—the instrument can be fully reconfigured in 10 to 20 minutes. This unmatched flexibility provides a platform that can easily be adapted to meet constantly evolving application needs and ever advancing detection technologies while accommodating most budgets. With multiple detection modes, including AlphaScreen and HTRF, as well as 1536-well microplate compatibility to support high-through screening, the SpectraMax Paradigm Reader is ideal for drug discovery & development, particularly for assay development, lead identification, and lead optimization.

FilterMax F3 & F5 Multi-Mode Readers
The new, patented FilterMax F Series Platform delivers a unique combination of value, performance, and sensitivity, putting high-performance multi-detection capabilities into the hands of any life science researcher. This unique filter-based platform delivers unmatched assay performance across a broad range of life science applications, and currently offers two models: the F3 with absorbance, fluorescence, and luminescence detection modes and the F5 with those same modes plus fluorescence polarization and time resolved fluorescence modes.